The FASN levels are higher in GC patients’ serum and tissues, and FASN and membranous HER2 (mHER2) expression are linked, with patients with concordant FASN and mHER2 expression having worse prognosis [24,57,58,59,60,61,62]. This evidence concerns the gene FASN and gastric cancer.